Physician profile
John B Crew
NPI 1174776611
$3,656.33
in general payments reported to CMS, 2019-2025
54 companies · $837 in 2025
The $837 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $206 · 2021: $163 · 2022: $428 · 2023: $690 · 2024: $847 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.66 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $481.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $304.55 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $263.76 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals Lp | $237.28 | 2019-2025 | Imfinzi, Lynparza |
| Janssen Biotech, INC. | $162.09 | 2019-2024 | Carvykti, Tecvayli, Talvey |
| Eisai INC. | $142.06 | 2019-2025 | |
| Genzyme Corporation | $138.76 | 2021-2024 | |
| Stemline Therapeutics INC. | $133.52 | 2024-2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $109.85 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.36 | 2019-2024 | Fruzaqla, Ninlaro |
| Pfizer INC. | $107.16 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.03 | 2019-2025 | Libtayo |
| Blueprint Medicines Corporation | $103.13 | 2023-2025 | Ayvakit |
| Amgen INC. | $93.28 | 2019-2022 | |
| Novocure INC. | $84.57 | 2020-2025 | Optune Lua (Novottf-200t) |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.